TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
13/11/2024
Voltar para busca
Dado oficial do USPTO
U-LOAD
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
19/11/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
12/11/2021
Data de registro
05/03/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/03/2024
Última transação
19/11/2024
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DK
Examinador
ALLEN, BIANCA
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
I. A. (pessoa física)
Representantes
Miriam D. Trudell Davis Graham & Stubbs LLP
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry and sciencein the nature of immune related chemicals for immune cell analysisimmune cell monitoringimmune cell detection and immune cell stimulation and immune related chemicals used in science in the nature of MHC monomer and multimer reagentsMR1 monomer and multimer reagentsCD1 monomer and multimer reagentsantibodiesantigen monomer and multimer reagentsreagentsdiagnostic agentscontrol reagentsoligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; diagnostic reagents for diagnostic being research useother than medical and veterinary usescientific use; research diagnostic reagents for scientific use; diagnostic test materials for scientific and diagnosticother than medical and veterinarypurposesdiagnostic reagents and preparationsexcept for medical or veterinary use; diagnostic kits for scientific and diagnosticother than medical and veterinarypurposes comprised of diagnostic reagents and preparationsexcept for medical or veterinary use and also comprised of immune related chemicals used in sciencein the nature of MHC monomer and multimer reagentsMR1 monomer and multimer reagentsCD1 monomer and multimer reagentsantibodiesantigen monomer and multimer reagentsreagentsdiagnostic agentscontrol reagentsoligonucleotide conjugated multimer reagents in the nature of DNA/RNA oligo conjugated multimer reagents; assays for research purposes; biochemical reagents for non-medical purposesother than medical and veterinary; chemical and diagnostic preparations for analysis for research purposes related to vaccines and immunotherapycancer vaccinesborrelia vaccinesTB-vaccinesHIV-vaccinesCMV-vaccines and other vaccinesfor use in scientific research in connection with therapy and immunotherapyin particularfor use in cancer therapycancer immunotherapyfor analysis of T-cell lymphomaT-cell infiltration of solid tumors and tissue; chemicaldiagnostic preparations for analysis for research purposes related to analysis of infectious diseasesautoimmunity and for use in scientific research in connection with toxicological studiestransplantationimmune monitoringvaccines and T-cell monitoring; chemical reagents for other than medicinal and veterinary purposes
Classe 5
Preparations for pharmaceutical purposespharmaceutical preparations for the treatment of cancerT-cell lymphomaT-cell infiltration of solid tumors and tissueT-cell diseases in bloodtransplantation related diseases and diseases related to immune suppressionautoimmune disease and infectious diseases; preparations for medical purposesdiagnostic preparations for medical purposes and medical preparations for treatment of cancerT-cell lymphomaT-cell infiltration of solid tumors and tissueT-cell diseases in bloodtransplantation related diseases and diseases related to immune suppressionautoimmune disease and infectious diseases; chemical-pharmaceutical preparations for treatment of cancerT-cell lymphomaT-cell infiltration of solid tumors and tissueT-cell diseases in bloodtransplantation related diseases and diseases related to immune suppressionautoimmune disease and infectious diseases; diagnostic preparations for medical purposes; vaccines; diagnostic preparations for analysis for medical purposeshereunder for each of the abovementioned preparations for medical analysis of vaccinesimmunotherapeutics and cellular therapiesin particular cancer vaccines and immunotherapeuticsborrelia vaccinesTB-vaccinesHIV-vaccines and CMV-vaccinesT-cell therapiesfor use in connection with cancer therapy or other therapyfor medical analysis and treatment of T-cell lymphomaT-cell infiltration of solid tumors and tissuefor infectious diseases; diagnostic preparations for analysis for medical purposeshereunder for use in connection with toxicological studiestransplantationimmune monitoringvaccines and T-cell monitoring
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
13/11/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
13/11/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/06/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/03/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
05/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
19/12/2023
PUBO
PUBLISHED FOR OPPOSITION
19/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
18/12/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
29/11/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
29/11/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/11/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/11/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/11/2023
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
08/11/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
14/08/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
26/07/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
26/07/2023
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
20/07/2023
GNFR
FINAL REFUSAL E-MAILED
20/07/2023
CNFR
FINAL REFUSAL WRITTEN
20/07/2023
DOCK
ASSIGNED TO EXAMINER
21/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
27/04/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
27/04/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/04/2023
RFNT
REFUSAL PROCESSED BY IB
14/11/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/10/2022
RFRR
REFUSAL PROCESSED BY MPU
27/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/09/2022
CNRT
NON-FINAL ACTION WRITTEN
01/09/2022
DOCK
ASSIGNED TO EXAMINER
24/08/2022
MAFR
APPLICATION FILING RECEIPT MAILED
01/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
25/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
24/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace U-LOAD ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.